Tag Archives: healthcare

Spineart, the fast-growing spinal devices company, welcomes EGS Beteiligungen AG which invests CHF 50 million of growth equity

GIMV

04/06/2020 – 07:30 | Portfolio

 

Spineart today announces that it secured a CHF 50 million investment from EGS, which thus becomes a cornerstone investor in the company next to the Management and Gimv, its largest shareholder. These proceeds will be used to implement strategic clinical studies, accelerate Spineart’s organic growth in key markets, seize selective acquisition opportunities and for continued development and launch of superior technologies.

The company was co-founded in 2005 by Jérome Levieux and Stéphane Mugnier-Jacob, who both have over 20 years’ experience in the spine industry and co-lead Spineart (www.spineart.com). Over the past 4 years, Spineart has doubled its sales to reach a worldwide turnover of EUR 66 million in 2019, doubled its staff (+200 employees), strengthened its leadership team, vertically integrated manufacturing operations and increased significantly its profitability.

“We’re very happy to welcome EGS in Spineart’s capital. This new milestone will allow Spineart to write a new chapter of its successful story, by accelerating our expansion in the United States, our first market with more than 40% growth in 2019, and by strengthening our challenger position in Europe. This acceleration will be driven by the release of Spineart’s R&D pipeline, composed of multiple innovative technologies already designed and approved, combined with enhanced market access in strategic markets worldwide” said Jérôme Levieux and Stéphane Mugnier-Jabob, co-founders and co-CEOs of Spineart.

Dominik Sauter, Managing Director at EGS Beteiligungen AG, comments: “We have been impressed by the accelerated growth of Spineart in the last couple of years. Their ability to develop and market new products will also be key for future success. We look forward to be part of the Spineart team and to work with the board and management to further create value for all stakeholders.”

Bart Diels, Managing Partner and Head of Health & Care at Gimv, adds: “Having two longer term oriented, strong financial investors on board, gives Spineart a very solid foundation to continue its successful international growth. Together with EGS, we look forward to further supporting Spineart’s management team in realizing its ambitious growth plans”.

Spineart is a fast-growing Swiss spine company focused on simplifying spinal surgery by designing, developing and promoting safe and efficient solutions to surgeons, operating room teams and patients. Spineart is a pioneer in its field, having introduced unique patented and clinically validated technologies of motion preservation, fusion, minimally invasive surgery and fractures treatment. Spineart markets a complete portfolio combining traceable barcoded sterile packed implants with compact instrument sets, thus promoting greater safety, cost-efficiency, and compliance at the hospital.

Categories: News

Tags:

Axonics Modulation Technologies raises $130 million via public offering

GIlde Healthcare

Utrecht (the Netherlands), Cambridge, Massachusetts (USA) – Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that is commercializing novel implantable rechargeable sacral neuromodulation devices (r-SNM Systems) for the treatment of bladder and bowel dysfunction, announced the pricing of its public offering of 4,000,000 shares of its common stock at a public offering price of $32.50 per share, before underwriting discounts and commissions. The gross proceeds from the offering to Axonics are expected to be $130 million. In addition, the underwriters have a 30-day option to purchase up to an additional 600,000 shares. BofA Securities, Morgan Stanley and Wells Fargo Securities are acting as the joint book-running managers for the offering and representatives of the underwriters. SVB Leerink and Needham & Company are acting as co-managers for the offering.

Axonics anticipates using net proceeds from the offering to support the commercialization of its r-SNM System in the United States, Europe and Canada. Via its r-SNM Systems, Axonics enables improved care at affordable cost for millions of patients worldwide suffering from incontinence, reflecting Gilde Healthcare’s patient centric investment strategy.

About Axonics Modulation Technologies, Inc.
Axonics, based in Irvine, Calif., has developed and is commercializing novel implantable SNM devices for patients with urinary and bowel dysfunction.
For more information, visit the company’s website at www.axonics.com.

About Gilde Healthcare
Gilde Healthcare is a specialized healthcare investor managing over €1.4 billion ($1.5 billion) across two fund strategies: venture & growth capital and private equity. Gilde Healthcare’s venture & growth capital fund invests in fast growing companies active in digital health, medtech and therapeutics. The venture & growth companies are based in Europe and North America. Gilde Healthcare’s private equity fund invests in profitable European lower mid-market healthcare companies with a focus on the Benelux and DACH region. The private equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market.
For more information, visit the company’s website at www.gildehealthcare.com.

Gilde Healthcare is a specialized healthcare investor managing over €1.4 billion ($1.5 billion) across two fund strategies: venture & growth capital and private equity. Gilde Healthcare’s venture & growth capital fund invests in health tech and therapeutics. The venture & growth companies are based in Europe and North America. Gilde Healthcare’s private equity fund invests in profitable European lower mid-market healthcare companies with a focus on the Benelux and DACH region. The private equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market.

Categories: News

Tags:

Vapotherm raises $87 million via public offering

GIlde Healthcare

Utrecht (the Netherlands), Cambridge, Massachusetts (USA) – Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced the pricing of an underwritten public offering of 3,350,000 shares of its common stock at a price to the public of $26.00 per share. The gross proceeds from the offering to Vapotherm are expected to be $87 million. In addition, Vapotherm has granted the underwriters a 30-day option to purchase up to an additional 502,500 shares. BofA Securities and William Blair are acting as joint book-running managers for the offering. Canaccord Genuity is acting as lead manager and BTIG is acting as co-manager.
Vapotherm intends to use the net proceeds from this offering to hire additional sales and marketing personnel and expand marketing programs both in the United States and internationally. Hi-VNI Technology is mask-free noninvasive ventilatory support for spontaneously breathing patients and is a front-line tool for relieving respiratory distress — including COVID-related. Vapotherm enables improved care at affordable cost for millions of patients worldwide suffering from respiratory distress, reflecting Gilde Healthcare’s patient centric investment strategy.

About Vapotherm

Vapotherm, Inc. is a publicly traded developer and manufacturer of advanced respiratory technology based in Exeter, New Hampshire, USA. The Company develops innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic or acute breathing disorders. Over 2.2 million patients have been treated with Vapotherm Hi-VNI Technology. Hi-VNI Technology is mask-free noninvasive ventilatory support for spontaneously breathing patients and is a front-line tool for relieving respiratory distress—including hypercapnia, hypoxemia, and dyspnea. It allows for the fast, safe treatment of undifferentiated respiratory distress with one tool. Hi-VNI Technology’s mask-free interface delivers optimally conditioned breathing gases, making it comfortable for patients and reducing the risks associated with mask therapies. While being treated, patients can talk, eat, drink and take oral medication.
For more information, visit the company’s website at www.vapotherm.com.

About Gilde Healthcare

Gilde Healthcare is a specialized healthcare investor managing over €1.4 billion ($1.5 billion) across two fund strategies: venture & growth capital and private equity. Gilde Healthcare’s venture & growth capital fund invests in fast growing companies active in digital health, medtech and therapeutics. The venture & growth companies are based in Europe and North America. Gilde Healthcare’s private equity fund invests in profitable European lower mid-market healthcare companies with a focus on the Benelux and DACH region. The private equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market.
For more information, visit the company’s website at www.gildehealthcare.com.

Gilde Healthcare

Gilde Healthcare is a specialized healthcare investor managing over €1.4 billion ($1.5 billion) across two fund strategies: venture & growth capital and private equity. Gilde Healthcare’s venture & growth capital fund invests in health tech and therapeutics. The venture & growth companies are based in Europe and North America. Gilde Healthcare’s private equity fund invests in profitable European lower mid-market healthcare companies with a focus on the Benelux and DACH region. The private equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market.

Categories: News

Tags:

Onex to Acquire Independent Clinical Services

Onex

Toronto, April 16, 2020 – Onex Corporation (“Onex”) (TSX: ONEX) and its affiliated funds
today announced that it has agreed to acquire Independent Clinical Services Group Ltd. (“ICS”)
in partnership with the existing management team and with a reinvestment in the equity by the
former majority shareholder, TowerBrook Capital Partners LP. ICS is a leading specialised
staffing, workforce management solutions, and health and social services business operating
primarily in Europe and present across four continents globally. ICS’s 1,850 employees serve
over 2,000 clients from offices in 10 countries. The transaction is expected to close later this
year, subject to customary conditions and regulatory approvals. The terms of the transaction are
not being disclosed.

“ICS is committed to being a true partner to its clients in delivering both capacity and care at the
highest standard, and that is a commitment we want to continue and build on,” said Nigel
Wright, a Managing Director with Onex. “We are pleased to be partnering with the ICS
management team and look forward to supporting their growth for years to come.”
“Onex’ strong investment track record and history of supporting the teams it invests alongside
makes it an ideal partner for us,” said Mike Barnard, Chief Executive Officer of ICS. “Our first
priority is to provide high-quality healthcare staffing and services to our clients and partners
around the world. Onex is aligned with the strategic direction of our firm and we are excited to
work together in our next phase of growth.”
The investment will be made by Onex Partners V, Onex’ $7.2 billion fund.

About Onex
Founded in 1984, Onex invests and manages capital on behalf of its shareholders, institutional
investors and high net worth clients from around the world. Onex’ platforms include: Onex
Partners, private equity funds focused on larger opportunities in North America and Europe;
ONCAP, private equity funds focused on middle market and smaller opportunities in North
America; Onex Credit, which manages primarily non-investment grade debt through
collateralized loan obligations, private debt and other credit strategies; and Gluskin Sheff’s
actively managed public equity and public credit funds. In total, Onex has approximately
$38.4 billion of assets under management, of which approximately $7.2 billion is its own
shareholder capital. With offices in Toronto, New York, New Jersey and London, Onex and its
experienced management teams are collectively the largest investors across Onex’ platforms.
The Onex Partners and ONCAP businesses have assets of $42 billion, generate annual revenues
of $28 billion and employ approximately 171,000 people worldwide. Onex shares trade on the
Toronto Stock Exchange under the stock symbol ONEX.

For more information on Onex, visit
its website at www.onex.com. Onex’ security filings can also be accessed at www.sedar.com.
This news release may contain forward-looking statements that are based on management’s
current expectations and are subject to known and unknown uncertainties and risks, which could
cause actual results to differ materially from those contemplated or implied by such
forward-looking statements. Onex is under no obligation to update any forward-looking
statements contained herein should material facts change due to new information, future events
or otherwise.

For further information:
Claire Glossop Irani
Director, Client and Product Solutions
416.362.7711

 

Categories: News

Tags:

Yellowtail now part of conclusion ecosystem

NPM Capital

Conclusion has integrated Yellowtail into its ecosystem. With this, the IT service provider strengthens its position in the financial sector and in the field of digital transformations. Yellowtail is a leading fintech label in the Netherlands focusing on pension funds, banks and insurers. Yellowtail designs, builds and manages digital and data-driven software solutions for financial service providers, with the mission to improve the quality of consumers’ financial lives.

Yellowtail combines expertise of the financial market, IT and User Experience with innovative capacity and implementation power to develop innovative original solutions such as MyLife, Mortgage Assist and MyMortgage. Through these smart digital and data-driven software solutions, Yellowtail brings financial service providers closer to their customers, they can activate these customers better and provide them with advice that suits their financial situation. This gives consumers more direction to their financial future with relative ease.

The Key Control Dashboard platform with a strong position within central and local government is also part of the Yellowtail portfolio. The Key Control Dashboard offers an integrated approach to governance, risk and control in order to allow organizations to be demonstrably “in control” and to comply with the relevant standards frameworks (BIO, ISO27001, NEN7510) and legislation (AVG).

Matthijs Mons, managing director of Yellowtail: “As part of Conclusion, Yellowtail can really take the next step. We see multiple opportunities by working with Conclusion labels that better position us together with large accounts within the ecosystem and get more strength to take on large projects.” Yellowtail’s other managing directors, Robin Bouman, Edwin Lodder and Mark Leck, add: “With our domain knowledge and data driven expertise, Yellowtail contributes to the power of Conclusion as a digital transformation player.”

Engbert Verkoren, CEO at Conclusion (a participation of NPM Capital): “The fact that Yellowtail is now part of the ecosystem strengthens us as a transformation partner in the financial sector. A sustainable and personal customer relationship will become crucial for financial institutions in the coming years. With Yellowtail’s data-driven software solutions, we can help financial service providers in this (digital) transformation.”

Also read ‘IT service provider Conclusion number 1 in the Netherlands’
Also read ‘KWD Resultaatmanagment now part of Conclusion ecosysteem’

Categories: News

Tags:

Navamedic enters into distribution agreement for ThermaCare®

Reiten

Navamedic recently announced that they have entered into an exclusive distribution agreement with Angelini Pharma for ThermaCare® in the Nordics and the strategically important Dutch market. With the agreement, Navamedic strengthens its position in the Consumer Health segment and enters the important pain category.

ThermaCare® was launched by Procter & Gamble in 2001 and is an advanced pain therapy for back, neck and muscles, classified as a Medical Device class IIa. The therapy is applied as heat wraps which is activated upon contact with air and placed on pain points, exactly where the user needs it. ThermaCare® delivers up to 16 hours of pain relief, 8 hours while used and 8 hours after it has been taken off. The larger adhesive area makes it easy to re-adjust, and the single-use wraps are thin enough to be worn discreetly under clothing.

Angelina Pharma is a part of the Italian Angelini Group and they acquired the ThermaCare® global business rights (excluding North America) from GSK earlier this year. In the distribution agreement now entered into with Angelina Pharma, Navamedic will take over and accelerate marketing, sales and distribution of ThermaCare® in the Nordics and Netherlands from July 2020. The agreement has a duration of eight years, with options to extend.

For further info, please see company press release: http://www.navamedic.com/no/nyheter/2020/03/navamedic-asa-enters-into-distribution-agreement-for-thermacare-with-angelini-pharma/

 

Categories: News

Tags:

Northlane Capital Partners Invests in VMG Health

Northlane

BETHESDA, Md.–(BUSINESS WIRE)–Northlane Capital Partners (“NCP”) announced today that it has made an investment in VMG Health (“VMG”), a leading full-service valuation and transaction advisory firm exclusively focused on the healthcare industry. NCP invested in partnership with VMG’s existing management team and key employees, led by Founder and CEO Greg Koonsman.

“We are very excited to partner with VMG. The company’s compelling value proposition and best in class team, coupled with the continuously evolving healthcare regulatory landscape, provide a strong foundation for future growth.”

Tweet this

Founded in 1995, VMG Health provides compliance related transaction services including: business, real estate, and asset valuation, physician compensation plan design and valuation, buy side and sell side quality of earnings, litigation and dispute services, and reimbursement consulting. Additional information is available at www.vmghealth.com.

“I am thrilled that we have entered into a partnership with Northlane Capital Partners to continue our firm’s legacy of healthcare transaction expertise. We share a vision with NCP for the next phase of our company as the market leader in healthcare valuation, diligence services, and consulting. Our singular focus in healthcare allows us to differentiate our core services of healthcare business and real estate related valuation, quality of earnings and diligence, physician compensation consulting and valuation, and reimbursement related consulting. Now in our 25th year, we will continue to build the VMG Health brand which has been synonymous with expertise, quality, and responsiveness to our customers,” said Greg Koonsman, Founder and CEO of VMG.

Eugene Krichevsky, Partner at NCP, noted, “VMG is the clear leader in a niche within the healthcare sector where we can utilize our industry expertise and network to help create value. We look forward to working alongside Greg and the VMG team to continue to broaden VMG’s capabilities and customer base, both through organic growth initiatives and the acquisition of complementary service lines.”

Sean Eagle, Partner at NCP, added, “We are very excited to partner with VMG. The company’s compelling value proposition and best in class team, coupled with the continuously evolving healthcare regulatory landscape, provide a strong foundation for future growth.”

ABOUT NORTHLANE CAPITAL PARTNERS

Based in Bethesda, MD, Northlane Capital Partners is a private equity firm focused on key segments within the healthcare and business services sectors, where its principals have invested $1.5 billion of equity capital. NCP seeks investments in middle market companies based in North America with EBITDA of $5 million to $30 million. NCP’s strategy is to partner with industry leading companies and great management teams, aligning incentives to accelerate growth and build value. For more information, please visit www.northlanecapital.com.

Contacts

Eugene Krichevsky, Partner
(301) 841-1399

Sean Eagle, Partner
(301) 841-1377

JJ Carbonell, Vice President
(301) 841-1420

Categories: News

Tags:

Sun Capital Partners Affiliate Acquires West Dermatology

Sun Capital

Sun Capital Partners, Inc. (“Sun Capital”), a leading private investment firm focused on investing in market-leading companies, today announced that its affiliate has completed the acquisition of West Dermatology (“West” or “the Company”), a leading, clinical, cosmetic and research dermatology platform with 55+ clinic locations throughout Arizona, California and Nevada. Terms of the private transaction were not disclosed.

Founded in 1962 and headquartered in Newport Beach, Calif., West Dermatology is a rapidly growing practice management group focused exclusively on clinical research, medical dermatology services, and cosmetic dermatology. The Company offers more than 800,000 annual patients cosmetic and clinical expertise and continued care for common skin conditions, cancer prevention and remediation, elective cosmetic procedures as well as critical, specialty services such as dermatopathology, innovative research trials and Mohs microsurgery.

West Dermatology boasts a strong foundation in the healthcare community, including maintaining long-term membership and leadership participation with the American Academy of Dermatology, Skin Cancer Foundation, American College of Mohs Surgery, American Society for Dermatologic Surgery, and the American Academy of Allergy, Asthma and Immunology.

“Dermatology is a recession-resistant and growing industry within the broader retail health landscape, and West is a premier player poised to grow further in partnership with Sun Capital” said Marc Leder, Co-Chief Executive Officer of Sun Capital. “We are excited to begin working with CEO Chris Kane and his team and look forward to growing West organically and through continued best-in-class add-on acquisitions.”

West Dermatology has executed 22 acquisitions since 2016 and has recorded sustained multi-year organic growth at more than twice the industry rate as a portfolio company of Enhanced Healthcare Partners.

“Having undergone significant growth over the past five years, West is now at a point where we are prepared to leverage our core competencies to grow in partnership with Sun Capital,” said Kane. “We’re confident Sun Capital’s proven expertise will help us to enhance operations, and better fulfill our mission of serving each of our patients to the best of our ability, every day.”

“West is a true strategic platform that benefits from a carefully assembled portfolio of best-in-class providers, a strong management team prepared to execute an ambitious growth strategy, great strategic payor relationships, and a deep bench of clinical and cosmetic dermatologists recognized as true thought leaders,” added Daniel Florian, Managing Director at Sun Capital Partners. “With support from Sun Capital, West will accelerate its disciplined growth strategy and will further build on the Company’s legacy of excellence.”

For more information, please contact:

Emily Meringolo

Stanton

646-502-3559

emeringolo@StantonPRM.com

Categories: News

Tags:

JenaValve Technology Closes $50 Million Financing

GIMV

Equity Round led by Bain Capital Life Sciences

IRVINE, Calif. (February 5, 2020) – JenaValve Technology, Inc., developer and manufacturer of the
JenaValve Pericardial Transcatheter Aortic Valve Replacement (TAVR) System for the treatment of
aortic valve disease, announces that it has raised $50 million in an equity financing led by Bain Capital
Life Sciences. Additional participants in the financing included existing investors Andera Partners, Gimv,
Legend Capital, NeoMed Management, RMM, Valiance Life Sciences and VI Partners. The Company
also announces the appointment of Andrew Hack, MD, PhD, Managing Director of Bain Capital, to the
JenaValve Board of Directors.

“We are pleased to complete this financing led by new investor Bain Capital Life Sciences, a wellrespected name in healthcare, as well as strong participation from our existing venture investors,” said John Kilcoyne, JenaValve’s Chief Executive Officer. “This announcement comes on the heels of receiving Breakthrough Device designation from the U.S. Food and Drug Administration (FDA), which
allows for priority review of our Align Clinical Trial for the treatment of symptomatic, severe aortic
regurgitation (AR) and AR-dominant mixed aortic valve disease. Our TAVR system is differentiated in
that no other transcatheter valve device has FDA approval for patients suffering from severe AR who are
at high risk for surgery, which we believe is a multi-billion-dollar market opportunity. This financing
supports our ongoing clinical program and plans to file for U.S. Humanitarian Device Exemption (HDE)
approval in the second half of 2020.”

JenaValve is conducting a global multicenter clinical program for the treatment of patients with severe
AR and AR-dominant mixed aortic valve disease who are at high risk for surgery. Following completion
of the HDE portion of the trial, patient enrollment will continue in support of submitting a Premarket
Approval (PMA) application to the FDA under the Breakthrough Device program. The Company also
anticipates filing the JenaValve® for CE mark approval for both aortic stenosis and aortic regurgitation in
the second half of 2020.
“We welcome Dr. Hack to our Board and look forward to Bain Capital’s contribution to governance and
strategy,” added Mr. Kilcoyne. “Andrew’s industry knowledge and experience, as well as his success as
an institutional investor and chief financial officer will add valuable perspectives to our Board.”
Dr. Hack commented, “I’m delighted to join the JenaValve Board as the Company works to gain approval
for a solution to a significant unmet medical need. JenaValve’s focus on advancing a breakthrough
technology with the ability to improve patient lives embodies the characteristics we seek at Bain Capital
Life Sciences. We are committed to providing both financial assistance and oversight in support of
JenaValve’s success.”

Dr. Hack has served as a Managing Director at Bain Capital Life Sciences since 2019. He previously
served as Chief Financial Officer of Editas Medicine (Nasdaq: EDIT) and as a healthcare portfolio
manager at Millennium Management. Prior to that, he was a securities analyst at a number of healthcare focused hedge funds and investment banks. Dr. Hack received an MD and a PhD in molecular genetics
and cell biology from the University of Chicago.

About the JenaValve Transfemoral TAVR System
The JenaValve Pericardial TAVR System consists of a bioprosthesis comprised of a self-expanding nitinol
stent with a porcine pericardial valve manufactured using state-of-the-art tissue processing techniques.
The TAVR System is available in three sizes to treat a broad range of aortic annulus diameters.
The JenaValve Pericardial TAVR System is an investigational device, and is not available for sale in the
United States or internationally.

About Bain Capital Life Sciences
Bain Capital Life Sciences (www.baincapitallifesciences.com) pursues investments in biopharmaceutical,
specialty pharmaceutical, medical device, diagnostics and enabling life science technology companies
globally. The team focuses on companies that both drive medical innovation across the value chain and
enable that innovation to improve the lives of patients with unmet medical needs. Since 1984, Bain
Capital has developed global reach, deep expertise and a proven track record in life sciences industries
across its Private Equity, Credit, Public Equity and Venture business units. Bain Capital Life Sciences
builds on the differentiated skillset and enables the firm to pursue opportunities created by several longterm trends in healthcare.

About JenaValve
JenaValve Technology, Inc., with locations in Irvine, Calif., Leeds, U.K. and Munich, Germany, develops
and manufactures transcatheter aortic valve replacement (TAVR) systems to treat patients suffering from
aortic valve disease. The Company is in clinical development of its next-generation transfemoral TAVR
system in both the U.S. and CE mark countries for treating patients with aortic stenosis and/or aortic
regurgitation. In addition to Bain Capital Life Sciences, JenaValve is backed by European and Asian
investors, including Andera Partners (formerly Edmond de Rothschild Investment Partners), Gimv
(Euronext: GIMB), Legend Capital, NeoMed Management, RMM, Valiance Life Sciences and VI
Partners. Additional information is available at www.jenavalve.com.
###
Investor and Media Contact:
Matt Clawson
W2Opure
(949) 370-8500
mclawson@w2ogroup.com

Categories: News

Tags:

JenaValve Technology Closes $50 Million Financing

GIMV

IRVINE, Calif. (February 5, 2020) – JenaValve Technology, Inc., developer and manufacturer of the
JenaValve Pericardial Transcatheter Aortic Valve Replacement (TAVR) System for the treatment of
aortic valve disease, announces that it has raised $50 million in an equity financing led by Bain Capital
Life Sciences. Additional participants in the financing included existing investors Andera Partners, Gimv,
Legend Capital, NeoMed Management, RMM, Valiance Life Sciences and VI Partners. The Company
also announces the appointment of Andrew Hack, MD, PhD, Managing Director of Bain Capital, to the
JenaValve Board of Directors.

“We are pleased to complete this financing led by new investor Bain Capital Life Sciences, a wellrespected name in healthcare, as well as strong participation from our existing venture investors,” said John Kilcoyne, JenaValve’s Chief Executive Officer. “This announcement comes on the heels of receiving Breakthrough Device designation from the U.S. Food and Drug Administration (FDA), which
allows for priority review of our Align Clinical Trial for the treatment of symptomatic, severe aortic
regurgitation (AR) and AR-dominant mixed aortic valve disease. Our TAVR system is differentiated in
that no other transcatheter valve device has FDA approval for patients suffering from severe AR who are
at high risk for surgery, which we believe is a multi-billion-dollar market opportunity. This financing
supports our ongoing clinical program and plans to file for U.S. Humanitarian Device Exemption (HDE)
approval in the second half of 2020.”

JenaValve is conducting a global multicenter clinical program for the treatment of patients with severe
AR and AR-dominant mixed aortic valve disease who are at high risk for surgery. Following completion
of the HDE portion of the trial, patient enrollment will continue in support of submitting a Premarket
Approval (PMA) application to the FDA under the Breakthrough Device program. The Company also
anticipates filing the JenaValve® for CE mark approval for both aortic stenosis and aortic regurgitation in
the second half of 2020.

“We welcome Dr. Hack to our Board and look forward to Bain Capital’s contribution to governance and
strategy,” added Mr. Kilcoyne. “Andrew’s industry knowledge and experience, as well as his success as
an institutional investor and chief financial officer will add valuable perspectives to our Board.”
Dr. Hack commented, “I’m delighted to join the JenaValve Board as the Company works to gain approval
for a solution to a significant unmet medical need. JenaValve’s focus on advancing a breakthrough
technology with the ability to improve patient lives embodies the characteristics we seek at Bain Capital
Life Sciences. We are committed to providing both financial assistance and oversight in support of
JenaValve’s success.”

Dr. Hack has served as a Managing Director at Bain Capital Life Sciences since 2019. He previously
served as Chief Financial Officer of Editas Medicine (Nasdaq: EDIT) and as a healthcare portfolio
manager at Millennium Management. Prior to that, he was a securities analyst at a number of healthcarefocused hedge funds and investment banks. Dr. Hack received an MD and a PhD in molecular genetics
and cell biology from the University of Chicago.

About the JenaValve Transfemoral TAVR System
The JenaValve Pericardial TAVR System consists of a bioprosthesis comprised of a self-expanding nitinol
stent with a porcine pericardial valve manufactured using state-of-the-art tissue processing techniques.
The TAVR System is available in three sizes to treat a broad range of aortic annulus diameters.
The JenaValve Pericardial TAVR System is an investigational device, and is not available for sale in the
United States or internationally.

About Bain Capital Life Sciences
Bain Capital Life Sciences (www.baincapitallifesciences.com) pursues investments in biopharmaceutical,
specialty pharmaceutical, medical device, diagnostics and enabling life science technology companies
globally. The team focuses on companies that both drive medical innovation across the value chain and
enable that innovation to improve the lives of patients with unmet medical needs. Since 1984, Bain
Capital has developed global reach, deep expertise and a proven track record in life sciences industries
across its Private Equity, Credit, Public Equity and Venture business units. Bain Capital Life Sciences
builds on the differentiated skillset and enables the firm to pursue opportunities created by several longterm trends in healthcare.

About JenaValve
JenaValve Technology, Inc., with locations in Irvine, Calif., Leeds, U.K. and Munich, Germany, develops
and manufactures transcatheter aortic valve replacement (TAVR) systems to treat patients suffering from
aortic valve disease. The Company is in clinical development of its next-generation transfemoral TAVR
system in both the U.S. and CE mark countries for treating patients with aortic stenosis and/or aortic
regurgitation. In addition to Bain Capital Life Sciences, JenaValve is backed by European and Asian
investors, including Andera Partners (formerly Edmond de Rothschild Investment Partners), Gimv
(Euronext: GIMB), Legend Capital, NeoMed Management, RMM, Valiance Life Sciences and VI
Partners. Additional information is available at www.jenavalve.com.

Investor and Media Contact:
Matt Clawson
W2Opure
(949) 370-8500
mclawson@w2ogroup.com

Categories: News

Tags: